araag2/HINT huggingface dataset:
Clinical trial NCT02366143 (phase 3, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody, bevacizumab, carboplatin, paclitaxel
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status 0 or 1

          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC

          -  Participants with no prior treatment for Stage IV non-squamous NSCLC

          -  Known PD-L1 status as determined by immunohistochemistry assay performed on previously
             obtained archival tumor tissue or tissue obtained from a biopsy at screening

          -  Measurable disease as defined by RECIST v1.1

          -  Adequate hematologic and end organ function

        Exclusion Criteria:

        Cancer-Specific Exclusions:

          -  Active or untreated central nervous system metastases

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome

        General Medical Exclusions:

          -  Pregnant or lactating women

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography scan. History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted

          -  Positive test for human immunodeficiency virus

          -  Active hepatitis B or hepatitis C

          -  Severe infection within 4 weeks prior to randomization

          -  Significant cardiovascular disease

          -  Illness or condition that interferes with the participant's capacity to understand,
             follow and/or comply with study procedures

        Exclusion Criteria Related to Medications:

          -  Prior treatment with cluster of differentiation 137 agonists or immune checkpoint
             blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies
Clinical trial NCT02367781 (phase 3, status: completed)
Conditions: carcinoma, non-squamous non-small cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody, carboplatin, nab-paclitaxel, pemetrexed
SMILES: CCCNCC(O)COC1=C(C=CC=C1)C(=O)CCC1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group performance status of 0 or 1

          -  Histologically or cytologically confirmed, Stage IV non-squamous NSCLC

          -  Participants with no prior treatment for Stage IV non-squamous NSCLC

          -  Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at
             screening

          -  Measurable disease, as defined by RECIST v1.1

          -  Adequate hematologic and end organ function

        Exclusion Criteria:

        Cancer-Specific Exclusions:

          -  Active or untreated central nervous system metastases

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome

        General Medical Exclusions:

          -  Pregnant or lactating women

          -  History of autoimmune disease

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography scan. History of radiation pneumonitis in the radiation
             field (fibrosis) is permitted

          -  Positive test for human immunodeficiency virus

          -  Active hepatitis B or hepatitis C

          -  Severe infection within 4 weeks prior to randomization

          -  Significant cardiovascular disease

          -  Illness or condition that interferes with the participant's capacity to understand,
             follow and/or comply with study procedures

        Exclusion Criteria Related to Medications:

          -  Prior treatment with cluster of differentiation 137 agonists or immune checkpoint
             blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies
Clinical trial NCT02373202 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: sarilumab, sulfasalazine, leflunomide, bucillamine, tacrolimus, mizoribine
SMILES: OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1, CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F, [H][C@@](CS)(N=C(O)C(C)(C)S)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, NC(=O)C1=C(O)N(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion criteria:

        Diagnosis of rheumatoid arthritis (RA), according to the American College of
        Rheumatology/The European League Against Rheumatism (ACR/EULAR) 2010 Rheumatoid Arthritis
        Classification Criteria with >=3 months disease duration.

        Moderately to severely active RA defined as:

          -  At least 4 of 68 tender joints and 4 of 66 swollen joints at screening visit.

          -  High sensitivity C-Reactive Protein (hs-CRP) >=4 mg/L or Erythrocyte Sedimentation
             Rate (ESR) >=28 mm/hr at screening visit.

        For the combination stratum:

        Participants who had continuous treatment with non-biologic DMARDs other than MTX for at
        least 12 weeks prior to the randomization and on a stable dose for a minimum of 6 weeks
        prior to screening.

        For the monotherapy stratum:

        Participants who per investigator judgment were any of inappropriate, intolerant or
        inadequate to MTX treatment.

        Exclusion criteria:

        Participants <20 years of age. Prior treatment with tumor necrosis factor (TNF) antagonists
        or any other RA-directed biologic agents without the appropriate off-drug period prior to
        screening.

        Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R)
        antagonist therapies, including but not limited to tocilizumab or sarilumab.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT02376790 (phase 3, status: completed)
Conditions: psoriatic arthritis
ICD codes: L40.52
Drugs: etanercept, methotrexate, placebo to etanercept, placebo to methotrexate
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subject must have a diagnosis of psoriatic arthritis (PsA) by the Classification
             Criteria for Psoriatic Arthritis (CASPAR) criteria.

          -  Subject has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline.

          -  Subject has an active psoriatic skin lesion

          -  Subject is naïve to etanercept and any other biologic for the treatment for PsA or
             psoriasis.

          -  Subject has no prior use of methotrexate for PsA.

          -  Subject has no history of tuberculosis

          -  Subject has a negative test for tuberculosis, hepatitis B and C.

        Exclusion Criteria:

          -  Subject has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or
             immunodeficiency syndromes, including human immunodeficiency virus (HIV) infection.

          -  Subject has any active infection (including chronic or localized infections) for which
             anti-infectives were indicated within 4 weeks prior to the first dose of
             investigational product.

          -  Subject has a serious infection, defined as requiring hospitalization or intravenous
             anti-infectives within 8 weeks prior to the first dose of investigational product.
Clinical trial NCT02378480 (phase 3, status: completed)
Conditions: bacterial infections, skin structures and soft tissue infections
ICD codes: A49.9, A04.9, A04.8, A49.8
Drugs: omadacycline, linezolid
SMILES: [H][C@@]12CC3=C(C=C(CNCC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C, CC(=O)NC[C@H]1CN(C(=O)O1)C1=CC(F)=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients, ages 18 years or older who have signed the informed consent

          -  Has a qualifying skin and skin structure infection

          -  Female patients must not be pregnant at the time of enrollment

          -  Must agree to a reliable method of birth control during the study and for 30 days
             following the last dose of study drug

        Exclusion Criteria:

          -  Infections where the outcome is strongly influenced by factors other than
             protocol-defined treatment and procedures, that require antibacterial treatment for
             greater than 14 days

          -  Evidence of significant immunological disease

          -  Severe sepsis or septic shock

          -  Has a history of hypersensitivity or allergic reaction to any tetracycline or to
             linezolid

          -  Has received an investigational drug within past 30 days

          -  Women who are pregnant or nursing
Clinical trial NCT02382276 (phase 3, status: completed)
Conditions: alcohol dependence
ICD codes: F10.20, F10.24, F10.27, F10.280, F10.281, F10.282, F10.288
Drugs: nalmefene hydrochloride
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have completed Study 339-14-001

          -  Patients who have signed the informed consent form for Study 339-14-002

        Exclusion Criteria:

          -  The patient has a clinically significant unstable illness (eg, complication of New
             York Heart Association (NYHA) class III or IV heart failure or angina pectoris, renal
             function disorder with estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73
             m2, hepatic failure, and neoplastic disorder)

          -  The patient has a clinically significant abnormal electrocardiogram (ECG) which is
             inappropriate for the participation in the trial in the opinion of the investigator or
             subinvestigator
Clinical trial NCT02383238 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Type 2 diabetes

          2. HbA1c > 6.5%

          3. age > 18 years

          4. male and females

        Exclusion Criteria:

          1. age > 75 years

          2. HbA1c > 10 %,

          3. reduced renal function (eGFR < 60 ml/min/1.73 m²).

          4. insulin therapy, or any antidiabetic medication other than metformin.

          5. uncontrolled hypertension (> 180/>110 mmHg)

          6. cardiovascular event within the last 3 months

          7. Use of loop diuretics
Clinical trial NCT02383966 (phase 3, status: active, not recruiting)
Conditions: carcinoma, squamous cell of head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cetuximab, cisplatin/carboplatin, 5-fluorouracil
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of SCCHN

          -  Recurrent and/or metastatic SCCHN, not suitable for local-regional treatment

          -  Presence of at least 1 measurable lesion according to RECIST Version 1.1

          -  Signed written informed consent before any trial-related activities are carried out

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Other protocol-defined inclusion criteria could apply

        Exclusion Criteria:

          -  Prior systemic chemotherapy, except if given as part of multimodal treatment for
             locally advanced disease, that was completed within 6 months before randomization

          -  Surgery (excluding prior biopsy for diagnosis) or irradiation within 4 weeks before
             trial entry

          -  Previous treatment with monoclonal antibody or signal transduction inhibitors
             targeting epidermal growth factor receptor

          -  Nasopharyngeal carcinoma

          -  Known central nervous system metastasis and/or leptomeningeal disease

          -  Medical or psychological condition that would not permit the participant to complete
             the trial or sign informed consent

          -  Legal incapacity or limited legal capacity

          -  Other protocol-defined exclusion criteria could apply
Clinical trial NCT02384460 (phase 3, status: completed)
Conditions: epidermolysis bullosa
ICD codes: Q81.0, Q81.1, Q81.2, Q81.8, Q81.9, L12.30, L12.35
Drugs: sd-101-6.0 cream, placebo (sd-101-0.0) cream
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent form signed by the participant or participant's legal representative;
             if the participant was under the age of 18 but capable of providing assent, signed
             assent from the participant.

          -  Participant (or caretaker) must have been willing to comply with all protocol
             requirements.

          -  Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.

          -  Participant must have had 1 target wound (size 10 to 50 cm^2) at study entry.

          -  Participants 1 month and older.

          -  Target wound must have been present for at least 21 days.

        Exclusion Criteria:

          -  Participants who did not meet the entry criteria outlined above.

          -  Selected target wound did not have clinical evidence of local infection.

          -  Use of any investigational drug within the 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within the 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within the 30 days before enrollment.
             (Inhaled steroids and ophthalmic drops containing steroids were allowed).

          -  Use of systemic antibiotics within the 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated lesions.

          -  Pregnancy or breastfeeding during the study. (A urine pregnancy test was performed at
             screening and every 30 days until the final visit for female participants of
             childbearing potential).

          -  Females of childbearing potential who were not abstinent and not practicing a
             medically acceptable method of contraception.
Clinical trial NCT02384941 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: placebo, sotagliflozin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants had given written informed consent to participate in the study in
             accordance with local regulations.

          -  Adult participants 18 years and older with a diagnosis of T1D made at least 1 year
             prior to informed consent.

          -  Participants were being treated with insulin or insulin analog delivered. via
             continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

          -  Willing and able to perform self-monitored blood glucose (SMBG) and complete the study
             diary as required per protocol.

          -  At the Screening Visit, A1C must be between 7.0% to 11.0%.

          -  Females of childbearing potential must use an adequate method of contraception and
             have a negative pregnancy test .

        Exclusion Criteria:

          -  Use of antidiabetic agent other than insulin or insulin analog at the time of
             screening.

          -  Use of sodium-glucose cotransporter (SGLT) inhibitors within 8 weeks prior to
             randomization.

          -  Chronic systemic corticosteroid use.

          -  Type 2 diabetes mellitus (T2D), or severely uncontrolled T1D as determined by the
             Investigator.
Clinical trial NCT02387359 (phase 3, status: completed)
Conditions: irritable bowel syndrome characterized by constipation
ICD codes: B09, B08.8
Drugs: plecanatide, placebo
SMILES: [H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        •Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS
        based on ROME III diagnostic criteria and meeting criteria for diagnosis of the
        constipation predominant subtype - IBS-C

        Exclusion Criteria:

          -  Refusal or inability to sign informed consent for the trial

          -  Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day
             daily Calls, and/or complete electronic questionnaires

          -  BMI > 35 or < 18

          -  Women of child bearing potential who refuse to use an acceptable method of birth
             control for the duration of the trial

          -  Women who are pregnant or lactating

          -  Diagnosis of IBS-D or IBS-M

          -  Organic or obstructive disease of the small or large intestine

          -  Use of laxatives other than the study-supplied rescue medication (Dulcolax®,
             bisacodyl)

          -  Use of a prohibited concomitant medication within the time frame prior to screening
             outlined in the study protocol for that medication

          -  Unstable medical illness

          -  Bilirubin > 3X ULN in the absence of a conjugation defect

          -  Any laboratory value > 3X ULN unless discussed and approved by the study Medical
             Monitor
Clinical trial NCT02388906 (phase 3, status: active, not recruiting)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab, nivolumab
SMILES: COC1=CC=CC=C1OCC(O)CO, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  At least 15 years of age Except: where local regulations and/or institutional policies
             do not allow for subjects < 18 years of age (pediatric population) to participate. For
             those sites, the eligible subject population is ≥ 18 years of age

          -  Completely removed melanoma by surgery performed within 12 weeks of randomization

          -  Stage IIIb/C or Stage IV before complete resection

          -  No previous anti-cancer treatment

        Exclusion Criteria:

          -  Ocular or uveal melanoma

          -  History of carcinomatosis meningitis

          -  History of auto-immune disease

          -  Treatment directed against the resected melanoma that is administrated after the
             surgery

        Other protocol-defined inclusion/exclusion criteria apply
Clinical trial NCT02390219 (phase 3, status: completed)
Conditions: cystic fibrosis, advanced lung disease
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: lumacaftor, ivacaftor
SMILES: CC1=CC=C(NC(=O)C2(CC2)C2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC(=CC=C1)C(O)=O, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Homozygous for the F508del-CFTR mutation; historical genotype must be documented in
             the participant's source documents.

          -  Percent predicted FEV1 <40 of adjusted for age, sex, and height at Screening

        Exclusion Criteria:

          -  Participant currently receiving invasive mechanical ventilation.

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             participant

          -  Any clinically significant laboratory abnormalities at screening that would interfere
             with the study assessments or pose an undue risk for the subject

          -  A 12-lead electrocardiograms (ECG) demonstrating QTcF >450 msec at Screening

          -  History of solid organ or hematological transplantation

          -  History of alcohol or drug abuse in the past year

          -  Ongoing or prior participation in an investigational drug study (including studies
             investigating lumacaftor and/or ivacaftor) within 30 days of screening.

          -  Use of strong inhibitors, moderate inducers, or strong inducers of CYP3A

          -  Pregnant and nursing females: Females of childbearing potential must have a negative
             pregnancy test at Screening and Day 1.

          -  Sexually active subjects of reproductive potential who are not willing to follow the
             contraception requirements

          -  Use of beta blockers or the equivalent at Screening.